Instrumented human stem cells to see more during high throughput screening in drugInstrumented human stem cells to see more during high throughput screening in drug discovery and regenerative medicine

The hiPSCmore project aims to engineer fluorescent sensors in human induced pluripotent stem cells to reduce costs and enhance high-throughput imaging for drug discovery and regenerative medicine.

Subsidie
€ 150.000
2024

Projectdetails

Introduction

In hiPSCmore (read hiP-See-More), my team and I will engineer fluorescent sensors in the DNA of human induced pluripotent stem cells (hiPSC) so we can See More during high-throughput imaging screenings (imHTS) for drug discovery and regenerative medicine.

Background

Since hiPSCs can differentiate into most cell types in the human body, they are the ideal cell source for more predictive screening of therapies. Yet, hiPSCs are expensive to maintain and require external reagents to visualize pathophysiological changes, which adds to the screening cost and complexity.

In fact, the major hurdle in adopting hiPSCs for imHTS has been the price increase from <0.10 $/data point to 2+ $/data point.

Objectives

In the context of our ERC Stg, we genetically encoded fluorescent sensors for cell structure, function, and cell cycle progression directly into hiPSCs for in-vitro modeling of heart development. With those sensors, we can visualize pathophysiological changes through reagents provided by the cells themselves.

Thus, the more experiments we conduct, the cheaper they become. We believe this is the strategy to bring hiPSCs into imHTS, where testing millions of compounds reduces an experiment's marginal cost, similar to software.

To explore this opportunity, we envision three main objectives:

  1. Technology feasibility. We will scale up the production of our SeeMore hiPSCs and validate their cost-effectiveness in drug screening and regenerative medicine applications.
  2. Business feasibility. We will analyze market dynamics and customer preferences in the drug screening and regenerative markets to define the most efficient go-to-market strategy.
  3. Executive management. We will work with stakeholders in our advisory board to delineate IPR, business strategy, and future fundraising opportunities for a SeeMore spin-off company.

Conclusion

Through these activities, the SeeMore spin-off will incorporate the right mix of tech development and business savvy in its own DNA, so it can "seize more" of the HTS market.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-5-2024
Einddatum31-10-2025
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • UNIVERSITA DEGLI STUDI DI PAVIApenvoerder
  • DAY ONE SOCIETA A RESPONSABILITA LIMITATA

Land(en)

Italy

Vergelijkbare projecten binnen European Research Council

ERC Proof of...

Low-cost, high-throughput quantitative phase microscopy

This project aims to develop a low-cost high-content screening platform using novel imaging technology to democratize access to advanced research tools in life sciences.

€ 150.000
ERC Proof of...

High-throughput combinatory drugs testing on in vitro 3D cells model platform

The project aims to develop a microfluidic platform for high-throughput screening of drug combinations in 3D cultures to enhance drug discovery and identify synergistic therapies for breast cancer.

€ 150.000
ERC Proof of...

Next-gen fluorescence imaging for research and theranostics

The project aims to develop the TriScanner, a novel fluorescence microscope that enhances imaging speed, resolution, and sensitivity for multicellular systems in research and clinical applications.

€ 150.000
ERC Starting...

Deciphering signalling pathway dynamics during cell-fate commitment in stem cells

i-SignalTrace is a CRISPR/Cas9-based molecular recorder designed to track signaling pathways and lineage information in stem cells, enhancing differentiation protocols for advanced cellular therapies.

€ 1.500.000
ERC Consolid...

Dissecting the molecular regulation of hematopoietic stem cell emergence using pluripotent stem cells to improve ex vivo therapies

This project aims to develop methods for generating and expanding hematopoietic stem cells from patient-specific induced pluripotent stem cells to overcome transplantation barriers and enhance therapies.

€ 2.000.000

Vergelijkbare projecten uit andere regelingen

Mkb-innovati...

High Throughput Cell contractility system for rapid drug evaluation

Cytocypher en Optics11 ontwikkelen samen een prototype van een high throughput screening systeem voor het functioneel meten van hartspiercellen, ter bevordering van cardiologisch onderzoek.

€ 193.900
EIC Transition

Bringing 3D cardiac tissues to high throughput for drug discovery screens

Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.

€ 1.457.500
Mkb-innovati...

DETACT - Detection of Enzymes and muTAtions for Cancer Treatment

Cytura Therapeutics en ENPICOM ontwikkelen een innovatieve diagnostische assay voor vroege kankerdetectie door het meten van enzymactiviteit en mutatiepatronen in bloedcellen.

€ 215.845
EIC Pathfinder

AI-powered platform for autologous iPSC manufacturing

The project aims to develop an AI-guided microfluidic device for the standardized, cost-effective mass production of personalized iPSCs to enhance cancer therapies and tissue regeneration.

€ 3.999.225
EIC Pathfinder

NOn-VIral gene modified STEM cell therapy

This project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application.

€ 3.644.418